Showing results (1-10 of 224) with videos related to
Sort By:
Pageof 23
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
Emerging Strategies in Treating Double Hit LymphomasChadi Nabhan, Anthony R MatoJAMA Oncology|July 21, 2017
Biosimilars in Oncology in the United States: A ReviewChadi Nabhan, Sandeep Parsad, Anthony R Mato, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many OptionsNitin Jain, Philip Thompson, Alessandra Ferrajoli, et al.Clinical Lymphoma, Myeloma & Leukemia|August 23, 2017
Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative ReviewAnthony R Mato, Meghan C Thompson, Chadi Nabhan, et al.Clinical Lymphoma & Myeloma|October 20, 2005
The emerging role of alemtuzumab in chronic lymphocytic leukemiaChadi NabhanLeukemia & Lymphoma|March 28, 2012
Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?Chadi Nabhan, Jayesh MehtaLeukemia & Lymphoma|April 28, 2016
Use of class I histone deacetylase inhibitor romidepsin in combination regimensAdam Petrich, Chadi NabhanClinical Lymphoma, Myeloma & Leukemia|October 4, 2016
Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?Maital Bolshinsky, Chadi NabhanCancer Biology & Therapy|December 28, 2017
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemiaAnthony R Mato, Suparna Clasen, Peter Pickens, et al.Seminars in Oncology|February 14, 2002
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemiaChadi Nabhan, Steven T RosenPageof 23